Christopher Missling, Anavex Life Sciences CEO
A win in Rett syndrome? Not so fast — biotech shares slide amid concerns of last-minute trial changes
Normally, an announcement that a Phase III trial met all primary and secondary efficacy and safety endpoints is sure to get a biotech’s shares up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
